|
Delayed
Toronto S.E.
09:30:00 2025-04-25 EDT
|
5-day change | 1st Jan Change | ||
| 0.005000 CAD | -.--% |
|
-.--% | - |
| 07-28 | Aequus Pharmaceuticals Inc. Announces Board Resignations | CI |
| 07-28 | Aequus Pharmaceuticals Inc. Announces Resignation of Doug Janzen from Chief Executive Officer, Effective July 27, 2026 | CI |
| Market Cap | 663K 470K 413K 388K 355K 45.07M 668K 4.66M 1.81M 22.98M 1.77M 1.73M 74.5M | P/E 2023 |
-1.12x | P/E 2024 | -0.61x |
|---|---|---|---|---|---|
| Enterprise Value | 7.23M 5.13M 4.5M 4.23M 3.87M 491M 7.28M 50.8M 19.69M 250M 19.25M 18.83M 812M | EV / Sales 2023 |
32.2x | EV / Sales 2024 | 13.5x |
| Free-Float |
85.32% | Yield 2023 * |
-
| Yield 2024 | - |
| 3 years | 0 |  | 0.05 |
| 5 years | 0 | | 0.13 |
| 10 years | 0 | | 0.48 |
| Manager | Title | Age | Since |
|---|---|---|---|
Douglas Janzen
CEO | Chief Executive Officer | 58 | 2013-01-02 |
| Director | Title | Age | Since |
|---|---|---|---|
Douglas Janzen
CHM | Chairman | 58 | 2014-12-09 |
Marc Lustig
BRD | Director/Board Member | 53 | 2021-02-14 |
| Director/Board Member | - | 2025-09-11 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 12/30/25 | Buy | Director | 4,000 | 0.0030% | ||
| 12/30/25 | Buy | Director | 16,000 | 0.0121% | ||
| 12/30/25 | Buy | Director | 120,000 | 0.0905% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | -.--% | -.--% | -85.71% | 470K | |
| +3.43% | +3.50% | +60.79% | +115.97% | 1,026B | |
| +0.56% | +0.23% | +53.28% | +68.99% | 649B | |
| -0.23% | +0.09% | +20.12% | +70.88% | 468B | |
| +0.06% | +0.61% | +39.82% | +45.62% | 352B | |
| +1.16% | +2.53% | +21.60% | +28.61% | 271B | |
| -0.24% | -0.23% | +10.62% | +10.77% | 256B | |
| -0.16% | +6.62% | +45.02% | +51.73% | 220B | |
| -0.38% | -0.03% | +32.70% | +101.58% | 188B | |
| +0.30% | -9.43% | -31.91% | -60.30% | 170B | |
| Average | +0.47% | +1.13% | +25.20% | +34.82% | 359.91B | |
| Weighted average by Cap. | +1.12% | +1.26% | +38.77% | +67.71% |
| 2023 | 2024 | |
|---|---|---|
| Net sales | 255K 181K 159K 149K 136K 17.32M 257K 1.79M 695K 8.83M 679K 664K 28.63M | 584K 414K 364K 342K 313K 39.7M 589K 4.11M 1.59M 20.24M 1.56M 1.52M 65.63M |
| Net income | -2.96M -2.1M -1.85M -1.74M -1.59M -201M -2.99M -20.84M -8.08M -103M -7.9M -7.73M -333M | -2.18M -1.54M -1.36M -1.27M -1.17M -148M -2.19M -15.31M -5.94M -75.45M -5.8M -5.67M -245M |
| Net Debt | 4.89M 3.47M 3.05M 2.86M 2.62M 333M 4.93M 34.4M 13.34M 170M 13.04M 12.75M 550M | 6.56M 4.66M 4.09M 3.84M 3.51M 446M 6.61M 46.14M 17.89M 227M 17.48M 17.1M 737M |
Employees
-
Sector
Pharmaceuticals
- Stock Market
- Stocks
- AQS Stock
Select your edition
All financial news and data tailored to specific country editions
